secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0000950170-24-036811
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences reports FY2023 net loss $76.4M; Phase 3 CoMpass trial enrolling with FDA SPA
--------------------------------------------------------------------------------

- Cash and equivalents $226.2M as of Dec 31, 2023; expected to fund operations into H2 2026.
- Net loss $22.1M Q4 2023 and $76.4M full year 2023 vs $16.6M and $58.8M prior year.
- R&D expenses $65.2M for FY2023, up from $42.2M due to Phase 3 start and manufacturing costs.
- Global Phase 3 CoMpass trial for small choroidal melanoma actively enrolling under FDA SPA; Phase 2 showed 80% tumor control, 90% vision preservation.
- Phase 1 bladder cancer trial ongoing; data expected mid-2024; first patient showed complete response after single dose with light activation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017024036811/0000950170-24-036811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017024036811/aura-20240327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer